Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Urol. Mar 24, 2015; 4(1): 68-74
Published online Mar 24, 2015. doi: 10.5410/wjcu.v4.i1.68
Published online Mar 24, 2015. doi: 10.5410/wjcu.v4.i1.68
Role of PCA3 test in clinical decision making for prostate cancer diagnosis
Vladimir Yutkin, Ali Al-Zahrani, Andrew Williams, Carlos Martinez, Jonathan Izawa, Joseph Chin, Uro-Oncology Fellowship Program, Schulich School of Medicine, University of Western Ontario, London, Ontario N6A 3K7, Canada
Vladimir Yutkin, Guy Hidas, Dov Pode, Urology Department, Hadassah and Hebrew University Medical Center, Jerusalem 91120, Israel
Author contributions: All the authors contributed to this paper.
Supported by Performed using the internal funds of the Urology departments in both institutions.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Vladimir Yutkin, Urology Department, Hadassah and Hebrew University Medical Center, Ein Kerem Campus, POB 12000, Jerusalem 91120, Israel. yutkin@hadassah.org.il
Telephone: +972-2-6778135 Fax: +972-2-6778135
Received: May 17, 2014
Peer-review started: May 18, 2014
First decision: June 26, 2014
Revised: October 16, 2014
Accepted: November 17, 2014
Article in press: November 19, 2014
Published online: March 24, 2015
Peer-review started: May 18, 2014
First decision: June 26, 2014
Revised: October 16, 2014
Accepted: November 17, 2014
Article in press: November 19, 2014
Published online: March 24, 2015
Core Tip
Core tip: PCA3 is a molecular urine test, which is performed in patients with high risk for prostate cancer. In this international prospective study we demonstrate that it has better performance than routine serum prostate specific antigen test in men with previously negative prostate biopsies. We also show that patients and physicians tend to follow the recommendations for this test.